
|
|

|
|
|
OncoGenex Technologies Inc.
 |
Type of Company: |
Tech Company
|
Ownership: |
Publicly Traded (OGXI, NASDAQ) |
Company Size: |
45 Employees In BC (45 Total) |
Revenue: |
$0.50 Million CAD |
Year Founded: |
1991 |
Sector: |
Biotech/Life Sciences |
Region: |
Lower Mainland / South Coast
|
Tags: |
biopharmaceutical, cancer, therapeutics, drug development, oncology
|
|
 |
|
OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.
We currently have four product candidates in development: OGX-011, OGX-427, CSP-9222 and OGX-225. Three of the products are in clinical development.
We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.
In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:
- a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
- a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
- a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.
We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients ith CRPC via the Special Protocol Assessment (SPA) process.
|
|
|
|
|
 |
Date |
Type |
Amount |
Investors |
|
|
 |
Suite 400 – 1001 West Broadway Vancouver, BC V6H 4B1 Canada [ MAP ]
|
|
|
|
1 - 10 of 34 results
|
|
 |
|
 |
|
May 4, 2012
|
OncoGenex Pharmaceuticals Reports Financial Results and Reviews Clinical Development Highlights
|
|
Mar 16, 2012
|
OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
|
|
Mar 9, 2012
|
OncoGenex Pharmaceuticals Reports Financial Results for Fourth Quarter and Year End 2011
|
|
Jan 4, 2012
|
OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data
|
|
Nov 4, 2011
|
OncoGenex Pharmaceuticals Reports Financial Results for Third Quarter 2011
|
|
Oct 21, 2011
|
OncoGenex Pharmaceuticals Initiates Clinical Trial Evaluating OGX-427 in Advanced Bladder Cancer
|
|
Sep 19, 2011
|
OncoGenex Announces Completion of a Special Protocol Assessment Amendment with the FDA
|
|
Sep 7, 2011
|
OncoGenex Announces Publication of Custirsen Phase II Clinical Data in Leading Cancer Journals
|
|
May 10, 2011
|
OncoGenex Pharmaceuticals Reports Financial Results for First Quarter 2011
|
|
Apr 14, 2011
|
OncoGenex Pharmaceuticals Announces Issuance of Key European Patent for OGX-427
|
|
|
1 - 10 of 34 results
|
|
 |
|
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
|
|
|